Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 14 |
| List of Tables | 13 | 2 |
| List of Figures | 15 | 1 |
| Introduction | 16 | 1 |
| Global Markets Direct Report Coverage | 16 | 1 |
| Plaque Psoriasis (Psoriasis Vulgaris) Overview | 17 | 1 |
| Therapeutics Development | 18 | 1 |
| Pipeline Products for Plaque Psoriasis (Psoriasis Vulgaris) Overview | 18 | 1 |
| Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics under Development by Companies | 19 | 5 |
| Plaque Psoriasis (Psoriasis Vulgaris) Pipeline Products Glance | 24 | 4 |
| Late Stage Products | 24 | 1 |
| Clinical Stage Products | 25 | 1 |
| Early Stage Products | 26 | 1 |
| Unknown Stage Products | 27 | 1 |
| Plaque Psoriasis (Psoriasis Vulgaris) Products under Development by Companies | 28 | 6 |
| Plaque Psoriasis (Psoriasis Vulgaris) Companies Involved in Therapeutics Development | 34 | 55 |
| AbbVie Inc | 34 | 1 |
| AbGenomics International, Inc. | 35 | 1 |
| Almirall, S.A. | 36 | 1 |
| Alteogen Inc. | 37 | 1 |
| Amgen Inc. | 38 | 1 |
| AstraZeneca Plc | 39 | 1 |
| Avexxin AS | 40 | 1 |
| BIOCAD | 41 | 1 |
| Biocon Limited | 42 | 1 |
| Bionovis SA | 43 | 1 |
| Boehringer Ingelheim GmbH | 44 | 1 |
| Bristol-Myers Squibb Company | 45 | 1 |
| CalciMedica, Inc. | 46 | 1 |
| Can-Fite BioPharma Ltd. | 47 | 1 |
| Cell Medica Limited | 48 | 1 |
| Cellceutix Corporation | 49 | 1 |
| Coherus BioSciences, Inc. | 50 | 1 |
| Eli Lilly and Company | 51 | 1 |
| Epirus Biopharmaceuticals, Inc. | 52 | 1 |
| Exicure, Inc. | 53 | 1 |
| Forward Pharma A/S | 54 | 1 |
| Genor BioPharma Co Ltd | 55 | 1 |
| GlaxoSmithKline Plc | 56 | 1 |
| Idera Pharmaceuticals, Inc. | 57 | 1 |
| Johnson &Johnson | 58 | 1 |
| Kadmon Corporation, LLC | 59 | 1 |
| Kang Stem Biotech Co., Ltd. | 60 | 1 |
| KPI Therapeutics, Inc. | 61 | 1 |
| LEO Pharma A/S | 62 | 1 |
| Lipidor AB | 63 | 1 |
| Lupin Limited | 64 | 1 |
| Lycera Corp. | 65 | 1 |
| Maruho Co., Ltd. | 66 | 1 |
| MetrioPharm AG | 67 | 1 |
| Mitsubishi Tanabe Pharma Corporation | 68 | 1 |
| Momenta Pharmaceuticals, Inc. | 69 | 1 |
| Mycenax Biotech Inc. | 70 | 1 |
| NeuClone Pty Ltd | 71 | 1 |
| Novartis AG | 72 | 1 |
| Oncobiologics, Inc. | 73 | 1 |
| Pfizer Inc. | 74 | 1 |
| Promius Pharma, LLC | 75 | 1 |
| Protalix BioTherapeutics, Inc. | 76 | 1 |
| Provectus Biopharmaceuticals, Inc. | 77 | 1 |
| Sandoz International GmbH | 78 | 1 |
| Shanghai Celgen Bio-Pharmaceutical Co., Ltd. | 79 | 1 |
| Sucampo Pharmaceuticals, Inc. | 80 | 1 |
| Sun Pharma Advanced Research Company Ltd. | 81 | 1 |
| Takeda Pharmaceutical Company Limited | 82 | 1 |
| TheraMAB LLC | 83 | 1 |
| Therapeutic Proteins International, LLC | 84 | 1 |
| UCB S.A. | 85 | 1 |
| Valeant Pharmaceuticals International, Inc. | 86 | 1 |
| XBiotech Inc | 87 | 1 |
| Ziarco Pharma Ltd | 88 | 1 |
| Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Assessment | 89 | 14 |
| Assessment by Monotherapy Products | 89 | 1 |
| Assessment by Combination Products | 90 | 1 |
| Assessment by Target | 91 | 4 |
| Assessment by Mechanism of Action | 95 | 4 |
| Assessment by Route of Administration | 99 | 2 |
| Assessment by Molecule Type | 101 | 2 |
| Drug Profiles | 103 | 168 |
| (betamethasone dipropionate + calcipotriene) Drug Profile | 103 | 1 |
| (halobetasol propionate + tazarotene) Drug Profile | 104 | 1 |
| AbGn-168H Drug Profile | 105 | 2 |
| adalimumab biosimilar Drug Profile | 107 | 2 |
| adalimumab biosimilar Drug Profile | 109 | 2 |
| adalimumab biosimilar Drug Profile | 111 | 2 |
| adalimumab biosimilar Drug Profile | 113 | 1 |
| adalimumab biosimilar Drug Profile | 114 | 1 |
| adalimumab biosimilar Drug Profile | 115 | 1 |
| adalimumab biosimilar Drug Profile | 116 | 1 |
| adalimumab biosimilar Drug Profile | 117 | 3 |
| adalimumab biosimilar Drug Profile | 120 | 1 |
| adalimumab biosimilar Drug Profile | 121 | 1 |
| adalimumab biosimilar Drug Profile | 122 | 2 |
| adalimumab biosimilar Drug Profile | 124 | 2 |
| adalimumab biosimilar Drug Profile | 126 | 1 |
| adalimumab biosimilar Drug Profile | 127 | 1 |
| adalimumab biosimilar Drug Profile | 128 | 1 |
| adalimumab biosimilar Drug Profile | 129 | 1 |
| adalimumab biosimilar Drug Profile | 130 | 1 |
| adalimumab biosimilar Drug Profile | 131 | 1 |
| amiselimod hydrochloride Drug Profile | 132 | 2 |
| AST-005 Drug Profile | 134 | 1 |
| AVX-001 Drug Profile | 135 | 1 |
| bimekizumab Drug Profile | 136 | 2 |
| BMS-986165 Drug Profile | 138 | 1 |
| BMS-986202 Drug Profile | 139 | 2 |
| brodalumab Drug Profile | 141 | 6 |
| BTX-1308 Drug Profile | 147 | 1 |
| C-82 Drug Profile | 148 | 1 |
| calcipotriene Drug Profile | 149 | 1 |
| certolizumab pegol Drug Profile | 150 | 11 |
| CJM-112 Drug Profile | 161 | 1 |
| CM-2489 Drug Profile | 162 | 1 |
| dalazatide Drug Profile | 163 | 5 |
| DFD-06 Drug Profile | 168 | 1 |
| dimethyl fumarate Drug Profile | 169 | 2 |
| dimethyl fumarate Drug Profile | 171 | 1 |
| DLX-105 Drug Profile | 172 | 3 |
| DNX-114 Drug Profile | 175 | 1 |
| DNX-514 Drug Profile | 176 | 1 |
| etanercept Drug Profile | 177 | 1 |
| etanercept biosimilar Drug Profile | 178 | 2 |
| etanercept biosimilar Drug Profile | 180 | 1 |
| etanercept biosimilar Drug Profile | 181 | 2 |
| etanercept biosimilar Drug Profile | 183 | 1 |
| etanercept biosimilar Drug Profile | 184 | 1 |
| etanercept biosimilar Drug Profile | 185 | 3 |
| etanercept biosimilar Drug Profile | 188 | 1 |
| etanercept biosimilar Drug Profile | 189 | 2 |
| Furestem-CD Drug Profile | 191 | 1 |
| GK-664S Drug Profile | 192 | 1 |
| GSK-2831781 Drug Profile | 193 | 1 |
| GSK-2981278 Drug Profile | 194 | 1 |
| GSK-2982772 Drug Profile | 195 | 1 |
| guselkumab Drug Profile | 196 | 4 |
| IDP-122 Drug Profile | 200 | 1 |
| IMO-8400 Drug Profile | 201 | 6 |
| IMP-731 Drug Profile | 207 | 1 |
| infliximab biosimilar Drug Profile | 208 | 1 |
| infliximab biosimilar Drug Profile | 209 | 1 |
| infliximab biosimilar Drug Profile | 210 | 3 |
| infliximab biosimilar Drug Profile | 213 | 1 |
| infliximab biosimilar Drug Profile | 214 | 3 |
| infliximab biosimilar Drug Profile | 217 | 1 |
| infliximab biosimilar Drug Profile | 218 | 1 |
| KD-025 Drug Profile | 219 | 5 |
| KM-133 Drug Profile | 224 | 5 |
| LEO-32731 Drug Profile | 229 | 1 |
| LNP-1955 Drug Profile | 230 | 1 |
| LP-0113 Drug Profile | 231 | 1 |
| LY-3074828 Drug Profile | 232 | 1 |
| LYC-30937 Drug Profile | 233 | 2 |
| M-7040 Drug Profile | 235 | 1 |
| MC-201 Drug Profile | 236 | 1 |
| MP-1032 Drug Profile | 237 | 2 |
| namilumab Drug Profile | 239 | 1 |
| pefcalcitol Drug Profile | 240 | 1 |
| PF-06700841 Drug Profile | 241 | 1 |
| PH-10 Drug Profile | 242 | 3 |
| piclidenoson Drug Profile | 245 | 8 |
| RA-18C3 Drug Profile | 253 | 2 |
| risankizumab Drug Profile | 255 | 3 |
| RTU-1096 Drug Profile | 258 | 1 |
| TAB-08 Drug Profile | 259 | 2 |
| tildrakizumab Drug Profile | 261 | 2 |
| toreforant tartrate Drug Profile | 263 | 2 |
| ustekinumab biosimilar Drug Profile | 265 | 1 |
| ustekinumab biosimilar Drug Profile | 266 | 1 |
| ustekinumab biosimilar Drug Profile | 267 | 1 |
| ustekinumab biosimilar Drug Profile | 268 | 1 |
| ZPL-389 Drug Profile | 269 | 2 |
| Plaque Psoriasis (Psoriasis Vulgaris) Dormant Projects | 271 | 8 |
| Plaque Psoriasis (Psoriasis Vulgaris) Discontinued Products | 279 | 2 |
| Plaque Psoriasis (Psoriasis Vulgaris) Product Development Milestones | 281 | 12 |
| Featured News &Press Releases | 281 | 1 |
| Oct 11, 2016: Exicure Announces Positive Phase 1 Data for Topical Anti-TNF Compound AST-005 in Patients with Mild to Moderate Psoriasis | 281 | 1 |
| Oct 03, 2016: CIMZIA (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis | 282 | 1 |
| Oct 01, 2016: New Phase 3 Data Show Significant Efficacy Versus Placebo And Superiority Of Guselkumab Versus Humira In Treatment Of Moderate To Severe Plaque Psoriasis | 283 | 2 |
| Oct 01, 2016: Sun Pharma to Announce Late-Breaking Results for Investigational IL-23p19 inhibitor, Tildrakizumab, Achieves Primary End Point in Both Phase-3 Studies in Patients with Moderate-to-Severe Plaque Psoriasis | 285 | 1 |
| Sep 28, 2016: Dermira to Present Data from CIMZIA Phase 3 Clinical Program at European Academy of Dermatology and Venereology Congress | 286 | 1 |
| Sep 26, 2016: AbbVie Presents Data on Risankizumab at the 25th European Academy of Dermatology and Venereology Congress | 286 | 1 |
| Sep 23, 2016: FDA Approves Amgens AMJEVITA (Adalimumab-Atto) For Treatment Of Seven Inflammatory Diseases | 287 | 1 |
| Sep 21, 2016: Kadmon Initiates Placebo-Controlled Phase 2 Clinical Trial Evaluating KD025 in Psoriasis | 288 | 1 |
| Sep 19, 2016: UCB receives positive EU CHMP opinion for CIMZIA (certolizumab pegol) AutoClicks Prefilled Pen | 288 | 1 |
| Aug 30, 2016: FDA approves Erelzi, a biosimilar to Enbrel | 289 | 1 |
| Aug 08, 2016: Coherus Biosciences Announces Positive Topline Phase Three Results For Chs-1420 (Humira Biosimilar Candidate) In Patients With Psoriasis | 290 | 1 |
| Aug 03, 2016: MetrioPharm Expands Patent Protection for its Lead Compound MP1032 | 290 | 1 |
| Jul 19, 2016: FDA Advisory Committee Recommends Approval Of Brodalumab For Treatment Of Moderate-To-Severe Plaque Psoriasis | 290 | 1 |
| Jul 17, 2016: SB5, An Adalimumab Biosimilar Referencing Humira, Accepted for Review by European Medicines Agency | 291 | 1 |
| Jul 13, 2016: Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases | 292 | 1 |
| Appendix | 293 | 2 |
| Methodology | 293 | 1 |
| Coverage | 293 | 1 |
| Secondary Research | 293 | 1 |
| Primary Research | 293 | 1 |
| Expert Panel Validation | 293 | 1 |
| Contact Us | 293 | 1 |
| Disclaimer | 294 | 1 |